Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ananta Ganjoo, Anuj Tripathi & Prabhakar Chetti. (2020) Structural assessment and identification of 11β-hydroxysteroid dehydrogenase type 1 inhibitors. Journal of Biomolecular Structure and Dynamics 38:16, pages 4928-4937.
Read now
Read now
Xiaochun Zhu, J. Greg Slatter, Maurice G. Emery, Molly R. Deane, Anna Akrami, Xiping Zhang, Dean Hickman, Gary L. Skiles & Raju Subramanian. (2013) Activity-based exposure comparisons among humans and nonclinical safety testing species in an extensively metabolized drug candidate. Xenobiotica 43:7, pages 617-627.
Read now
Read now
Keith Suckling. (2012) The landscape of drug discovery in atherosclerosis and dyslipidaemia revisited: an update of patenting activity. Expert Opinion on Therapeutic Patents 22:3, pages 199-204.
Read now
Read now
Thomas D Aicher, Steven A Boyd, Maralee McVean & Anthony Celeste. (2010) Novel therapeutics and targets for the treatment of diabetes. Expert Review of Clinical Pharmacology 3:2, pages 209-229.
Read now
Read now
Articles from other publishers (62)
Alessandro Rossi, Chiara Simeoli, Mariacarolina Salerno, Rosario Ferrigno, Roberto Della Casa, Annamaria Colao, Pietro Strisciuglio, Giancarlo Parenti, Rosario Pivonello & Daniela Melis. (2020) Imbalanced cortisol concentrations in glycogen storage disease type I: evidence for a possible link between endocrine regulation and metabolic derangement. Orphanet Journal of Rare Diseases 15:1.
Crossref
Crossref
Shivani Bhatt, Nabeel B Nabulsi, Songye Li, Zhengxin Cai, David Matuskey, Jason Bini, Soheila Najafzadeh, Michael Kapinos, Jim R Ropchan, Richard E Carson, Kelly P Cosgrove, Yiyun Huang & Ansel T Hillmer. (2019)
First in-human PET study and kinetic evaluation of [
18
F]AS2471907 for imaging 11β-hydroxysteroid dehydrogenase type 1
. Journal of Cerebral Blood Flow & Metabolism 40:4, pages 695-704.
Crossref
Crossref
Jun Li, Lawrence J. Kennedy, Steven J. Walker, Haixia Wang, James J. Li, Zhenqiu Hong, Stephen P. O’Connor, Xiang-yang Ye, Stephanie Chen, Shung Wu, David S. Yoon, Akbar Nayeem, Daniel M. Camac, Vidhyashankar Ramamurthy, Paul E. Morin, Steven Sheriff, Mengmeng Wang, Timothy W. Harper, Rajasree Golla, Ramakrishna Seethala, Thomas Harrity, Randolph P. Ponticiello, Nathan N. Morgan, Joseph R. Taylor, Rachel Zebo, Brad Maxwell, Frederick Moulin, David A. Gordon & Jeffrey A. Robl. (2018) Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1). ACS Medicinal Chemistry Letters 9:12, pages 1170-1174.
Crossref
Crossref
Christine Loerz & Edmund Maser. (2017) The cortisol-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in the pathogenesis of the metabolic syndrome. The Journal of Steroid Biochemistry and Molecular Biology 174, pages 65-71.
Crossref
Crossref
Katharina R. Beck, Teresa Kaserer, Daniela Schuster & Alex Odermatt. (2017) Virtual screening applications in short-chain dehydrogenase/reductase research. The Journal of Steroid Biochemistry and Molecular Biology 171, pages 157-177.
Crossref
Crossref
Haiyan Qian, Jiongjiong Chen, Youlu Pan & Jianzhong Chen. (2016) Molecular Modeling Studies of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors through Receptor-Based 3D-QSAR and Molecular Dynamics Simulations. Molecules 21:9, pages 1222.
Crossref
Crossref
Graeme R. Robb, Scott Boyd, Christopher D. Davies, Alexander G. Dossetter, Frederick W. Goldberg, Paul D. Kemmitt, James S. Scott & John G. Swales. (2015) Design of pyrazolo-pyrimidines as 11β-HSD1 inhibitors through optimisation of molecular electrostatic potential. MedChemComm 6:5, pages 926-934.
Crossref
Crossref
Conor Woods & Jeremy W. Tomlinson. 2015. Glucocorticoid Signaling. Glucocorticoid Signaling
353
380
.
Guohua An, Wei Liu, David A. Katz, Gerard J. Marek, Walid Awni & Sandeep Dutta. (2014) Population pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens. Biopharmaceutics & Drug Disposition 35:7, pages 417-429.
Crossref
Crossref
Jun Li, Lawrence J. Kennedy, Haixia Wang, James J. Li, Steven J. Walker, Zhenqiu Hong, Stephen P. O’Connor, Akbar Nayeem, Daniel M. Camac, Paul E. Morin, Steven Sheriff, Mengmeng Wang, Timothy Harper, Rajasree Golla, Ramakrishna Seethala, Thomas Harrity, Randolph P. Ponticiello, Nathan N. Morgan, Joseph R. Taylor, Rachel Zebo, David A. Gordon & Jeffrey A. Robl. (2014) Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1). ACS Medicinal Chemistry Letters 5:7, pages 803-808.
Crossref
Crossref
James S. ScottFrederick W. GoldbergAndrew V. Turnbull. (2013) Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1). Journal of Medicinal Chemistry 57:11, pages 4466-4486.
Crossref
Crossref
Carlos F. Lagos, Andrea Vecchiola, Fidel Allende, Cristobal A. Fuentes, Juan E. Tichauer, Carolina Valdivia, Sandra Solari, Carmen Campino, Alejandra Tapia-Castillo, Rene Baudrand, Pia Villarroel, Mariana Cifuentes, Gareth I. Owen, Cristian A. Carvajal & Carlos E. Fardella. (2014) Identification of novel 11β-HSD1 inhibitors by combined ligand- and structure-based virtual screening. Molecular and Cellular Endocrinology 384:1-2, pages 71-82.
Crossref
Crossref
William McCoull, Martin Augustin, Caroline Blake, Anne Ertan, Elaine Kilgour, Stephan Krapp, Jane E. Moore, Nicholas J. Newcombe, Martin J. Packer, Amanda Rees, John Revill, James S. Scott, Nidhal Selmi, Stefan Gerhardt, Derek J. Ogg, Stefan Steinbacher & Paul R. O. Whittamore. (2014) Identification and optimisation of 3,3-dimethyl-azetidin-2-ones as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Med. Chem. Commun. 5:1, pages 57-63.
Crossref
Crossref
Xiang-Yang Ye, David Yoon, Stephanie Y. Chen, Akbar Nayeem, Rajasree Golla, Ramakrishna Seethala, Mengmeng Wang, Timothy Harper, Bogdan G. Sleczka, Atsu Apedo, Yi-Xin Li, Bin He, Mark Kirby, David A. Gordon & Jeffrey A. Robl. (2014) Synthesis and structure–activity relationship of 2-adamantylmethyl tetrazoles as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Bioorganic & Medicinal Chemistry Letters 24:2, pages 654-660.
Crossref
Crossref
Wu‐Kuang Yeh & Richard G. Peterson. 2013. Enzyme Technologies. Enzyme Technologies
131
162
.
Sang-Uk Kang. (2013) GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119. Drug Discovery Today 18:23-24, pages 1309-1315.
Crossref
Crossref
Isabelle Vögeli, Hans H Jung, Bernhard Dick, Sandra K Erickson, Robert Escher, John W Funder, Felix J Frey & Geneviève Escher. (2013) Evidence for a role of sterol 27-hydroxylase in glucocorticoid metabolism in vivo. Journal of Endocrinology 219:2, pages 119-129.
Crossref
Crossref
Carlos A. Penno, Stuart A. Morgan, Anna Vuorinen, Daniela Schuster, Gareth G. Lavery & Alex Odermatt. (2013) Impaired oxidoreduction by 11β-hydroxysteroid dehydrogenase 1 results in the accumulation of 7-oxolithocholic acid. Journal of Lipid Research 54:10, pages 2874-2883.
Crossref
Crossref
Sandra Hofer, Denise V. Kratschmar, Brigitte Schernthanner, Anna Vuorinen, Daniela Schuster, Alex Odermatt & Johnny Easmon. (2013) Synthesis and biological analysis of benzazol-2-yl piperazine sulfonamides as 11β-hydroxysteroid dehydrogenase 1 inhibitors. Bioorganic & Medicinal Chemistry Letters 23:19, pages 5397-5400.
Crossref
Crossref
Laura L. Gathercole, Gareth G. Lavery, Stuart A. Morgan, Mark S. Cooper, Alexandra J. Sinclair, Jeremy W. Tomlinson & Paul M. Stewart. (2013) 11β-Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects. Endocrine Reviews 34:4, pages 525-555.
Crossref
Crossref
Thomas Böhme, Christian K. Engel, Géraldine Farjot, Stefan Güssregen, Torsten Haack, Georg Tschank & Kurt Ritter. (2013) 1,1-Dioxo-5,6-dihydro-[4,1,2]oxathiazines, a novel class of 11ß-HSD1 inhibitors for the treatment of diabetes. Bioorganic & Medicinal Chemistry Letters 23:16, pages 4685-4691.
Crossref
Crossref
Mei-Ling Han, Yu Shen, Guo-Cai Wang, Ying Leng, Hua Zhang & Jian-Min Yue. (2013)
11β-HSD1 Inhibitors from
Walsura cochinchinensis
. Journal of Natural Products 76:7, pages 1319-1327.
Crossref
Crossref
Xu Deng, Yu Shen, Jing Yang, Juan He, Yu Zhao, Li-Yan Peng, Ying Leng & Qin-Shi Zhao. (2013) Discovery and structure–activity relationships of ent-Kaurene diterpenoids as potent and selective 11β-HSD1 inhibitors: Potential impact in diabetes. European Journal of Medicinal Chemistry 65, pages 403-414.
Crossref
Crossref
V. V. Lipson, M. G. Shirobokova & O. N. Petrova. (2013) 11β-Hydroxysteroid dehydrogenase type 1, a target for development of oral antidiabetic drugs (Review). Pharmaceutical Chemistry Journal 47:2, pages 80-86.
Crossref
Crossref
James S. Scott, Joanne deSchoolmeester, Elaine Kilgour, Rachel M. Mayers, Martin J. Packer, David Hargreaves, Stefan Gerhardt, Derek J. Ogg, Amanda Rees, Nidhal Selmi, Andrew Stocker, John G. Swales & Paul R. O. Whittamore. (2012)
Novel Acidic 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor with Reduced Acyl Glucuronide Liability: The Discovery of 4-[4-(2-Adamantylcarbamoyl)-5-
tert
-butyl-pyrazol-1-yl]benzoic Acid (AZD8329)
. Journal of Medicinal Chemistry 55:22, pages 10136-10147.
Crossref
Crossref
James S. Scott, Adrian L. Gill, Linda Godfrey, Sam D. Groombridge, Amanda Rees, John Revill, Paul Schofield, Pernilla Sörme, Andrew Stocker, John G. Swales & Paul R.O. Whittamore. (2012) Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors. Bioorganic & Medicinal Chemistry Letters 22:21, pages 6756-6761.
Crossref
Crossref
Xiangdong Su, Heather A. Halem, Mark P. Thomas, Cecile Moutrille, Michael D. Culler, Nigel Vicker & Barry V.L. Potter. (2012) Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors. Bioorganic & Medicinal Chemistry 20:21, pages 6394-6402.
Crossref
Crossref
Lianne Abrahams, Nina M Semjonous, Phil Guest, Agnieszka Zielinska, Beverly Hughes, Gareth G Lavery & Paul M Stewart. (2012) Biomarkers of hypothalamic–pituitary–adrenal axis activity in mice lacking 11β-HSD1 and H6PDH. Journal of Endocrinology 214:3, pages 367-372.
Crossref
Crossref
Eric Valeur, Serge Christmann-Franck, Franck Lepifre, Denis Carniato, Daniel Cravo, Christine Charon, Sophie Bozec, Djordje Musil, Per Hillertz, Liliane Doare, Fabien Schmidlin, Marc Lecomte, Melanie Schultz & Didier Roche. (2012) Structure-based design of 7-azaindole-pyrrolidine amides as inhibitors of 11β-hydroxysteroid dehydrogenase type I. Bioorganic & Medicinal Chemistry Letters 22:18, pages 5909-5914.
Crossref
Crossref
Amit Joharapurkar, Nirav Dhanesha, Gaurang Shah, Rajendra Kharul & Mukul Jain. (2012) 11β-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome. Pharmacological Reports 64:5, pages 1055-1065.
Crossref
Crossref
Mohammad M. Ahasan, Rowan Hardy, Christopher Jones, Kirren Kaur, Dominika Nanus, Maria Juarez, Stuart A. Morgan, Zaki Hassan‐Smith, Cécile Bénézech, Jorge H. Caamaño, Martin Hewison, Gareth Lavery, Elizabeth H. Rabbitt, Andrew R. Clark, Andrew Filer, Christopher D. Buckley, Karim Raza, Paul M. Stewart & Mark S. Cooper. (2012) Inflammatory regulation of glucocorticoid metabolism in mesenchymal stromal cells. Arthritis & Rheumatism 64:7, pages 2404-2413.
Crossref
Crossref
James S. ScottSuzanne S. BowkerJoanne deSchoolmeesterStefan GerhardtDavid HargreavesElaine KilgourAdele LloydRachel M. MayersWilliam McCoullNicholas J. NewcombeDerek OggMartin J. PackerAmanda ReesJohn RevillPaul SchofieldNidhal SelmiJohn G. SwalesPaul R. O. Whittamore. (2012)
Discovery of a Potent, Selective, and Orally Bioavailable Acidic 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor: Discovery of 2-[(3
S
)-1-[5-(Cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic Acid (AZD4017)
. Journal of Medicinal Chemistry 55:12, pages 5951-5964.
Crossref
Crossref
Yosup Rew, Michael DeGraffenreid, Xiao He, Juan C. Jaen, Dustin L. McMinn, Daqing Sun, Hua Tu, Stefania Ursu & Jay P. Powers. (2012) Discovery and optimization of benzenesulfonanilide derivatives as a novel class of 11β-HSD1 inhibitors. Bioorganic & Medicinal Chemistry Letters 22:11, pages 3786-3790.
Crossref
Crossref
E. J. Verspohl. (2012) Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes. Pharmacological Reviews 64:2, pages 188-237.
Crossref
Crossref
Liming Zhang, Junhua Chen, Mengmeng Ning, Qingan Zou, Ying Leng & Jianhua Shen. (2012) Synthesis and evaluation of piperidine urea derivatives as efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitors in diabetic ob/ob mice. Bioorganic & Medicinal Chemistry Letters 22:8, pages 2748-2752.
Crossref
Crossref
James S. Scott, Peter Barton, Stuart N. L. Bennett, Joanne deSchoolmeester, Linda Godfrey, Elaine Kilgour, Rachel M. Mayers, Martin J. Packer, Amanda Rees, Paul Schofield, Nidhal Selmi, John G. Swales & Paul R. O. Whittamore. (2012) Reduction of acyl glucuronidation in a series of acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors: the discovery of AZD6925. MedChemComm 3:10, pages 1264.
Crossref
Crossref
Fabienne Pradaux-Caggiano, Xiangdong Su, Nigel Vicker, Mark P. Thomas, Deborah Smithen, Heather A. Halem, Michael D. Culler & Barry V. L. Potter. (2012) Synthesis and evaluation of thiadiazole derivatives as inhibitors of 11β-hydroxysteroid dehydrogenase type 1. MedChemComm 3:9, pages 1117.
Crossref
Crossref
Zizhong Li, Peter Heffner & Yumin Gong. (2011) A gram-scale synthesis of [3,4-13C2,1α,7-2H2]cortisone. Journal of Labelled Compounds and Radiopharmaceuticals 54:14, pages 839-846.
Crossref
Crossref
Shung C. Wu, David Yoon, Janice Chin, Katy van Kirk, Ramakrishna Seethala, Rajasree Golla, Bin He, Thomas Harrity, Lori K. Kunselman, Nathan N. Morgan, Randolph P. Ponticiello, Joseph R. Taylor, Rachel Zebo, Timothy W. Harper, Wenying Li, Mengmeng Wang, Lisa Zhang, Bogdan G. Sleczka, Akbar Nayeem, Steven Sheriff, Daniel M. Camac, Paul E. Morin, John G. Everlof, Yi-Xin Li, Cheryl A. Ferraro, Kasia Kieltyka, Wilson Shou, Marianne B. Vath, Tatyana A. Zvyaga, David A. Gordon & Jeffrey A. Robl. (2011) Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1). Bioorganic & Medicinal Chemistry Letters 21:22, pages 6693-6698.
Crossref
Crossref
Xiang-Yang Ye, Stephanie Y. Chen, Akbar Nayeem, Rajasree Golla, Ramakrishna Seethala, Mengmeng Wang, Timothy Harper, Bogdan G. Sleczka, Yi-Xin Li, Bin He, Mark Kirby, David A. Gordon & Jeffrey A. Robl. (2011) Design, synthesis, and SAR studies of novel polycyclic acids as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1). Bioorganic & Medicinal Chemistry Letters 21:22, pages 6699-6704.
Crossref
Crossref
Xiangdong Su, Fabienne Pradaux-Caggiano, Nigel Vicker, Mark P. Thomas, Heather Halem, Michael D. Culler & Barry V. L. Potter. (2011) Adamantyl Ethanone Pyridyl Derivatives: Potent and Selective Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1. ChemMedChem 6:9, pages 1616-1629.
Crossref
Crossref
Alex Odermatt, Thierry Da Cunha, Carlos A. Penno, Charlie ChandsawangbhuwanaChristian Reichert, Armin Wolf, Min Dong & Michael E. Baker. (2011) Hepatic reduction of the secondary bile acid 7-oxolithocholic acid is mediated by 11β-hydroxysteroid dehydrogenase 1. Biochemical Journal 436:3, pages 621-629.
Crossref
Crossref
Denise V. Kratschmar, Anna Vuorinen, Thierry Da Cunha, Gerhard Wolber, Dirk Classen-Houben, Otto Doblhoff, Daniela Schuster & Alex Odermatt. (2011) Characterization of activity and binding mode of glycyrrhetinic acid derivatives inhibiting 11β-hydroxysteroid dehydrogenase type 2. The Journal of Steroid Biochemistry and Molecular Biology 125:1-2, pages 129-142.
Crossref
Crossref
Milana Maletic, Aaron Leeman, Michael Szymonifka, Steven S. Mundt, Hratch J. Zokian, Kashmira Shah, Jasminka Dragovic, Kathy Lyons, Rolf Thieringer, Anne H. Vosatka, James Balkovec & Sherman T. Waddell. (2011) Bicyclo[2.2.2]octyltriazole inhibitors of 11β-hydoxysteroid dehydrogenase type 1. Pharmacological agents for the treatment of metabolic syndrome. Bioorganic & Medicinal Chemistry Letters 21:8, pages 2568-2572.
Crossref
Crossref
Mark P ThomasBarry VL Potter. (2011) Crystal structures of 11β-hydroxysteroid dehydrogenase type 1 and their use in drug discovery. Future Medicinal Chemistry 3:3, pages 367-390.
Crossref
Crossref
Agnes E. Coutinho & Karen E. Chapman. (2011) The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Molecular and Cellular Endocrinology 335:1, pages 2-13.
Crossref
Crossref
Rawindra Gaware, Rupesh Khunt, Laszlo Czollner, Christian Stanetty, Thierry Da Cunha, Denise V. Kratschmar, Alex Odermatt, Paul Kosma, Ulrich Jordis & Dirk Claßen-Houben. (2011) Synthesis of new glycyrrhetinic acid derived ring A azepanone, 29-urea and 29-hydroxamic acid derivatives as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors. Bioorganic & Medicinal Chemistry 19:6, pages 1866-1880.
Crossref
Crossref
Clarence Hale & David J. St. Jean. 2011. Metabolic Syndrome. Metabolic Syndrome
423
458
.
Huaming Sheng & Hongbin Sun. (2011) Synthesis, biology and clinical significance of pentacyclic triterpenes: a multi-target approach to prevention and treatment of metabolic and vascular diseases. Natural Product Reports 28:3, pages 543.
Crossref
Crossref
Alexandra J. SinclairElizabeth A. WalkerMichael A. BurdonAndre P. van Beek, Ido P. Kema, Beverly A. HughesPhilip I. MurrayPeter G. NightingalePaul M. StewartSaaeha RauzJeremy W. Tomlinson. (2010) Cerebrospinal Fluid Corticosteroid Levels and Cortisol Metabolism in Patients with Idiopathic Intracranial Hypertension: A Link between 11β-HSD1 and Intracranial Pressure Regulation?. The Journal of Clinical Endocrinology & Metabolism 95:12, pages 5348-5356.
Crossref
Crossref
K. Raza, R. Hardy & M. S. Cooper. (2010) The 11 -hydroxysteroid dehydrogenase enzymes--arbiters of the effects of glucocorticoids in synovium and bone. Rheumatology 49:11, pages 2016-2023.
Crossref
Crossref
Christian Stanetty, Laszlo Czollner, Iris Koller, Priti Shah, Rawindra Gaware, Thierry Da Cunha, Alex Odermatt, Ulrich Jordis, Paul Kosma & Dirk Claßen-Houben. (2010) Synthesis of novel 3-amino and 29-hydroxamic acid derivatives of glycyrrhetinic acid as selective 11β-hydroxysteroid dehydrogenase 2 inhibitors. Bioorganic & Medicinal Chemistry 18:21, pages 7522-7541.
Crossref
Crossref
Erika Harno & Anne White. (2010) Will treating diabetes with 11β-HSD1 inhibitors affect the HPA axis?. Trends in Endocrinology & Metabolism 21:10, pages 619-627.
Crossref
Crossref
Scott P. Webster, Margaret Binnie, Kirsty M.M. McConnell, Karen Sooy, Peter Ward, Michael F. Greaney, Andy Vinter, T. David Pallin, Hazel J. Dyke, Matthew I.A. Gill, Ines Warner, Jonathan R. Seckl & Brian R. Walker. (2010) Modulation of 11β-hydroxysteroid dehydrogenase type 1 activity by 1,5-substituted 1H-tetrazoles. Bioorganic & Medicinal Chemistry Letters 20:11, pages 3265-3271.
Crossref
Crossref
Alex Odermatt & Lyubomir G. Nashev. (2010) The glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations. The Journal of Steroid Biochemistry and Molecular Biology 119:1-2, pages 1-13.
Crossref
Crossref
Claudia A. Staab & Edmund Maser. (2010) 11β-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation. The Journal of Steroid Biochemistry and Molecular Biology 119:1-2, pages 56-72.
Crossref
Crossref
Unmesh Shah, Craig D. Boyle, Samuel Chackalamannil, Hana Baker, Timothy Kowalski, Julie Lee, Giuseppe Terracina & Lili Zhang. (2010) Azabicyclic sulfonamides as potent 11β-HSD1 inhibitors. Bioorganic & Medicinal Chemistry Letters 20:5, pages 1551-1554.
Crossref
Crossref
Judith M. Rollinger, Denise V. Kratschmar, Daniela Schuster, Petra H. Pfisterer, Christel Gumy, Evelyne M. Aubry, Sarah Brandstötter, Hermann Stuppner, Gerhard Wolber & Alex Odermatt. (2010) 11β-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational approaches. Bioorganic & Medicinal Chemistry 18:4, pages 1507-1515.
Crossref
Crossref
Mark S. Cooper & Paul M. Stewart. (2009) 11β-Hydroxysteroid Dehydrogenase Type 1 and Its Role in the Hypothalamus-Pituitary-Adrenal Axis, Metabolic Syndrome, and Inflammation. The Journal of Clinical Endocrinology & Metabolism 94:12, pages 4645-4654.
Crossref
Crossref
A. Iovino & A.J. Scheen. (2009) La 11β-hydroxystéroïde déshydrogénase de type 1 – 2e partie Inhibition sélective pour traiter les anomalies métaboliques associées à l’obésité. Médecine des Maladies Métaboliques 3:6, pages 595-600.
Crossref
Crossref
A. Iovino, N. Paquot & A.J. Scheen. (2009) Rôle de l’enzyme 11β-hydroxystéroïde-déshydrogénase de type 1 dans le risque métabolique associé à l’obésitéRole of 11β-hydroxysteroid-dehydrogenase type 1 in the metabolic risk associated with obesity. Obésité 4:3-4, pages 181-188.
Crossref
Crossref
A. Iovino & A.J. Scheen. (2009) La 11β-hydroxystéroïde déshydrogénase de type 1 – 1re partie. Médecine des Maladies Métaboliques 3:5, pages 507-513.
Crossref
Crossref